Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

Climb Bio reported positive topline Phase 1 data for the subcutaneous formulation of budoprutug, showing robust B-cell depletion comparable to intravenous administration with a favorable safety profile. The FDA granted Fast Track Designation for budoprutug in primary membranous nephropathy (pMN), enhancing the regulatory pathway for this indication which already holds Orphan Drug status.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.